Health Care


  • Tenet Healthcare's $4.3 Billion Deal for Vanguard

    The "Squawk on the Street" team discusses the terms of Tenet's offer, and weigh in on Vodafone's $10 billion buyout offer for Kabel Deutschland.

  • Top doctors are calling attention to new guidance on screening for prostate cancer—the second-leading cause of cancer deaths for American men.

  • After the selling frenzy dies down, Cramer expects 3 sectors to emerge and ultimately rescue the bulls.

  • Independent of the debate on the Federal Reserve and interest rates, FTI Consulting's Barbara Ryan expects pharmaceutical and biotech stocks can continue to do well.

  • The AMA's new recognition of obesity as a "disease" could put a dent into insurers' bottom lines—at least in the short-term—but boost profits for makers of weight-loss drugs.

  • Obesity a Disease

    The American Medical Association says obesity should be classified as a disease. CNBC's Bertha Coombs reports AMA's Patrice Harris says the hope is for doctors to be more proactive in treating obese patients.

  • President Barack Obama speaks about the Affordable Care Act in San Jose, Calif.

    Small business owners are already curtailing hiring because of concerns over the cost of Obamacare, a recent survey found.

  • With the Dow up more than 2000 points for the year, Jim Cramer thinks now is a good time to single out stocks that haven’t rallied, but soon could.

  • Health care insurance

    Already sluggish health-care inflation is projected to slow down even more in 2014 as consumers, employers and the federal government continue looking to cut medical costs, a new report said Tuesday.

  • Months before Americans buy coverage under Obamacare, it's becoming clear that choices for millions of people will vary depending on where they live. The NYT reports.

  • Supreme Court Justice Stephen Breyer

    A Supreme Court decision gives the FTC the go-ahead to continue suing drug makers over deals that delay generic versions from being sold.

  • The Supreme Court says deals between pharmaceutical companies and their generic drug competitors can sometimes be illegal.

  • Jim Cramer believes this company is about to create immense value with the stroke of a pen.

  • Nutrisytem CEO Targets Battle of the Bulge

    Dawn Zier, President & CEO of Nutrisystem, discusses her company's plans to set up programs designed to meet the needs of people with special dietary needs, and its expansion into selling its products in Wal-Mart.

  • Biotech and drug companies say the benefits of genome research are on the way, and just as importantly, advances are pushing the technology toward affordability.

  • Justice Clarence Thomas

    A unanimous Supreme Court decision barred patents on naturally occurring DNA, but analysts said the ruling did little harm to biotech companies.

  • A patient is treated as part of a program in which some 600 doctors and support staff volunteer to treat people who have difficulty getting care.

    Like many of the 2,200-plus people who showed up for a 5:30 a.m. dental clinic last month, Patty Kennedy knows that bad teeth translate into poor employment prospects.

  • Cyclicals are heating up as the summer approaches and the economy starts to show signs of improvement, analysts say.

  • A worker in vaccine production at drugmaker GlaxoSmithKline in Saint-Amand-les-Eaux, France.

    GlaxoSmithKline fired the head of its R&D operations in China after a tipster spurred an inquiry that found "misrepresented" data were used in a multiple sclerosis study.

  • Obama administration to scrap age restrictions on the sale of morning-after pills, making the emergency contraception available to women and girls of any age without a prescription.

Contact Health Care


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about about our products and service. Privacy Policy.


  • Dan Mangan is a reporter covering health care for

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.